Abstract:Transcriptionally latent forms of replication-competent proviruses, present primarily in a small subset of memory CD4 + T cells, pose the primary barrier to a cure for HIV-1 infection because they are the source of the viral rebound that almost inevitably follows the interruption of antiretroviral therapy. Over the last 30 years, many of the factors essential for initiating HIV-1 transcription have been identified in studies performed using transformed cell lines, such as the Jurkat T-cell model. However, as highlighted in this review, several poorly understood mechanisms still need to be elucidated, including the molecular basis for promoter-proximal pausing of the transcribing complex and the detailed mechanism of the delivery of P-TEFb from 7SK snRNP. Furthermore, the central paradox of HIV-1 transcription remains unsolved: how are the initial rounds of transcription achieved in the absence of Tat? A critical limitation of the transformed cell models is that they do not recapitulate the transitions between active effector cells and quiescent memory T cells. Therefore, investigation of the molecular mechanisms of HIV-1 latency reversal and LRA efficacy in a proper physiological context requires the utilization of primary cell models. Recent mechanistic studies of HIV-1 transcription using latently infected cells recovered from donors and ex vivo cellular models of viral latency have demonstrated that the primary blocks to HIV-1 transcription in memory CD4 + T cells are restrictive epigenetic features at the proviral promoter, the cytoplasmic sequestration of key transcription initiation factors such as NFAT and NF-κB, and the vanishingly low expression of the cellular transcription elongation factor P-TEFb. One of the foremost schemes to eliminate the residual reservoir is to deliberately reactivate latent HIV-1 proviruses to enable clearance of persisting latently infected cells—the "Shock and Kill" strategy. For "Shock and Kill" to become efficient, effective, non-toxic latency-reversing agents (LRAs) must be discovered. Since multiple restrictions limit viral reactivation in primary cells, understanding the T-cell signaling mechanisms that are essential for stimulating P-TEFb biogenesis, initiation factor activation, and reversing the proviral epigenetic restrictions have become a prerequisite for the development of more effective LRAs.

Latency reversal and viral clearance to cure HIV-1

Research progress on HIV latency-reversing agents and its mechanism

Recent progress on functional cure for acquired immunodeficiency syndrome

HIV-1 Remission: Accelerating the Path to Permanent HIV-1 Silencing

HIV Persistence, Latency, and Cure Approaches: Where Are We Now?

The Rational Combination Strategy of Immunomodulatory Latency Reversing Agents and Novel Immunotherapy to Achieve HIV-1 Cure

Insights into the HIV-1 Latent Reservoir and Strategies to Cure HIV-1 Infection

Targeting Viral Transcription for HIV Cure Strategies

HIV-1 functional cure: will the dream come true?

Interventions during Early Infection: Opening a Window for an HIV Cure?

Strategies for human immunodeficiency virus cure：current status and future prospects

Effective and targeted latency reversal in CD4+ T cells from individuals on long term combined antiretroviral therapy initiated during chronic HIV-1 infection

The cell biology of HIV-1 latency and rebound

Humanized mice for studying HIV latency and potentially its eradication

Advancements in Developing Strategies for Sterilizing and Functional HIV Cures

Predicting the outcomes of treatment to eradicate the latent reservoir for HIV-1

Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirs

Current Status of Latency Reversing Agents Facing the Heterogeneity of HIV-1 Cellular and Tissue Reservoirs

Immune targeting of HIV-1 reservoir cells: a path to elimination strategies and cure

Selective elimination of host cells harboring replication-competent human immunodeficiency virus reservoirs: a promising therapeutic strategy for HIV cure

Research priorities for an HIV cure: International AIDS Society Global Scientific Strategy 2021